The Board of JW (Cayman) Therapeutics Co. Ltd. announced that, Dr. Debra Yu has been appointed as an independent non-executive Director and a member of each of the Remuneration Committee and Nomination Committee with effect from March 1, 2023. The biographical details of Dr. Yu are set forth below: Dr. Yu, alias Yu Jiuyun, aged 58, has more than 30 years of experience in strategy, business development, alliance management, investment banking, capital markets and venture capital.

She has been a director of ARYA Sciences Acquisition Corp. V (a company listed on Nasdaq under the symbol ARYE) and MeiraGTx (a company listed on Nasdaq under the symbol MGTX) since July 2021 and April 2022, respectively. She served as the president of LianBio (a company listed on Nasdaq under the symbol LIAN) from October 2019 to December 2022, where she also served as the chief business officer from October 2019 to September 2021 and the chief strategy officer from October 2021 to December 2022.

Prior to that, Dr. Yu held leadership positions at various reputable companies, including managing director and head of cross border investment banking of China Renaissance (US) Securities from August 2016 to September 2019, managing director of Labrador Advisors, LLC from July 2009 to June 2016, vice president and head of strategy of WuXi AppTec Inc. from 2008 to 2009 and senior director and team leader of the Pfizer Investments Group and Worldwide Business Development at Pfizer Inc. from 2004 to 2008. Earlier in her career, Dr. Yu served as the managing director and a general partner of two venture capital firms in the San Francisco Bay Area which focus their investments in the life sciences sector. Dr. Yu received a bachelor's degree in molecular biology from the Princeton University in June 1986 and subsequently received a medical degree from the Harvard Medical School in March 1992.

The Board further announces that with effect from March 1, 2023: (1) Dr. Yiping James Li, an executive Director, has been appointed as the chairman of the Nomination Committee; and (2) Mr. Yiu Leung Andy Cheung, an independent non-executive Director, has been appointed as a member of the Nomination Committee and the chairman of the Remuneration Committee.